Results 161 to 170 of about 2,506,792 (349)
Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1:physiological regulator and pharmacological target for energy partitioning [PDF]
Alberts +14 more
core +1 more source
Objective The aim was to determine patient, disease, and treatment characteristics associated with outcome in patients with primary angiitis of the central nervous system (PACNS) in a large multicenter German cohort. Methods In a retrospective, observational cohort study, we analyzed 163 adult patients who met the diagnostic criteria for PACNS.
Anna Lena Fisse +29 more
wiley +1 more source
Objective Spinal cord (SC) atrophy correlates with and predicts the underlying progressive biology in active and non‐active multiple sclerosis (MS), thereby providing a biomarker for clinical trials and patient management. Initiation of disease‐modifying therapy (DMT) may be followed by early pronounced central nervous system (CNS) volume loss due to ...
Simone Sacco +26 more
wiley +1 more source
Peptide/Antibody–Drug Conjugates for Therapeutic Applications in Inflammatory Disease
Peptide/antibody–drug conjugates (PADCs) combine ligand specificity and cleavable linkers to deliver drugs precisely to disease sites with minimal toxicity. While current approvals focus on oncology, this review examines their untapped potential in inflammatory diseases, detailing mechanisms of targeted delivery and highlighting advances that position ...
Yeongji Jang +5 more
wiley +1 more source
Objective Autoimmune diseases, such as systemic lupus erythematosus (SLE), are associated with pulmonary arterial hypertension (PAH), a condition that can lead to heart failure. However, whether T cells also contribute to the occurrence of PAH in SLE has not been clarified.
Shuliang Jing +9 more
wiley +1 more source
Antiphospholipid Syndrome: An Antibody‐Mediated Disease With Emerging Therapeutic Opportunities
Antiphospholipid syndrome (APS) is an autoimmune thromboinflammatory disease characterized by vascular thrombosis, pregnancy morbidity, and other manifestations driven by antiphospholipid autoantibodies. In this review, we present a clinical case that illustrates some diagnostic and therapeutic challenges in managing severe, relapsing APS ...
Thalia G. Newman, Jason S. Knight
wiley +1 more source
K. Butts +3 more
semanticscholar +1 more source
Objective To evaluate the applicability of the 2016 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR)/Paediatric Rheumatology International Trials Organisation (PRINTO) macrophage activation syndrome (MAS) classification criteria in patients with Still disease and systemic juvenile idiopathic arthritis ...
Remco G. A. Erkens +14 more
wiley +1 more source
Objective Despite the availability of biologic and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) to treat rheumatoid arthritis (RA), many patients do not experience optimized disease control. Glucocorticoids are effective but have safety risks.
Frank Buttgereit +13 more
wiley +1 more source

